-
Review Article
Pregestational Diabetes and Congenital Heart Defects
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(10):953-961
01-23-2022
Summary
Review ArticlePregestational Diabetes and Congenital Heart Defects
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(10):953-961
01-23-2022Views270See moreAbstract
Studies have consistently shown a significant increase in the risk of congenital heart defects in the offspring of diabetic mothers compared with those of nondiabetic pregnancies. Evidence points that all types of pregestational diabetes have the capacity of generating cardiac malformations in a more accentuated manner than in gestational diabetes, and there seems to be an increased risk for all congenital heart defects phenotypes in the presence of maternal diabetes. Currently, the application of some therapies is under study in an attempt to reduce the risks inherent to diabetic pregnancies; however, it has not yet been possible to fully prove their effectiveness. The present review aims to better understand the mechanisms that govern the association between pregestational diabetes and congenital heart defects and how maternal diabetes interferes with fetal cardiac development, as there is still a long way to go in the investigation of this complex process.
Views270
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Summary
Review ArticlePregestational Diabetes and Congenital Heart Defects
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(10):953-961
01-23-2022Views270See moreAbstract
Studies have consistently shown a significant increase in the risk of congenital heart defects in the offspring of diabetic mothers compared with those of nondiabetic pregnancies. Evidence points that all types of pregestational diabetes have the capacity of generating cardiac malformations in a more accentuated manner than in gestational diabetes, and there seems to be an increased risk for all congenital heart defects phenotypes in the presence of maternal diabetes. Currently, the application of some therapies is under study in an attempt to reduce the risks inherent to diabetic pregnancies; however, it has not yet been possible to fully prove their effectiveness. The present review aims to better understand the mechanisms that govern the association between pregestational diabetes and congenital heart defects and how maternal diabetes interferes with fetal cardiac development, as there is still a long way to go in the investigation of this complex process.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. -
Review Article
How to Reach the Best Ultrasound Performance in the Delivery Room
- Eduardo Félix Martins Santana
, - Renata Gomes Castello ,
- Maria Eduarda Tenório Passos ,
- Gabriela Carneiro Freitas Ribeiro ,
- Edward Araujo Júnior
01-23-2022
Summary
Review ArticleHow to Reach the Best Ultrasound Performance in the Delivery Room
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(11):1070-1077
01-23-2022- Eduardo Félix Martins Santana ,
- Renata Gomes Castello ,
- Maria Eduarda Tenório Passos ,
- Gabriela Carneiro Freitas Ribeiro ,
- Edward Araujo Júnior
Views195See moreAbstract
Ultrasonography is an instrument that is present in the maternal-fetal assessment throughout pregnancy and with widely documented benefits, but its use in intrapartum is becoming increasingly relevant. From the assessment of labor progression to the assessment of placental disorders, ultrasound can be used to correlate with physiological findings and physical examination, as its benefit in the delivery room cannot yet be proven. There are still few professionals with adequate training for its use in the delivery room and for the correct interpretation of data. Thus, this article aims to present a review of the entire applicability of ultrasound in the delivery room, considering the main stages of labor. There is still limited research in evidence-based medicine of its various possible uses in intrapartum, but it is expected that further studies can bring improvements in the quality of maternal and neonatal health during labor.
Views195This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Summary
Review ArticleHow to Reach the Best Ultrasound Performance in the Delivery Room
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(11):1070-1077
01-23-2022- Eduardo Félix Martins Santana ,
- Renata Gomes Castello ,
- Maria Eduarda Tenório Passos ,
- Gabriela Carneiro Freitas Ribeiro ,
- Edward Araujo Júnior
Views195See moreAbstract
Ultrasonography is an instrument that is present in the maternal-fetal assessment throughout pregnancy and with widely documented benefits, but its use in intrapartum is becoming increasingly relevant. From the assessment of labor progression to the assessment of placental disorders, ultrasound can be used to correlate with physiological findings and physical examination, as its benefit in the delivery room cannot yet be proven. There are still few professionals with adequate training for its use in the delivery room and for the correct interpretation of data. Thus, this article aims to present a review of the entire applicability of ultrasound in the delivery room, considering the main stages of labor. There is still limited research in evidence-based medicine of its various possible uses in intrapartum, but it is expected that further studies can bring improvements in the quality of maternal and neonatal health during labor.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. - Eduardo Félix Martins Santana
-
Review Article
The Effectiveness of Herbal Medicines on Cyclic Mastalgia: A Systematic Review on Meta-analysis
- Firoozeh Mirzaee ,
- Farzaneh Rashidi Fakari ,
- Masoudeh Babakhanian ,
- Nasibeh Roozbeh ,
- Masumeh Ghazanfarpour
01-23-2022
Summary
Review ArticleThe Effectiveness of Herbal Medicines on Cyclic Mastalgia: A Systematic Review on Meta-analysis
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(10):972-985
01-23-2022- Firoozeh Mirzaee ,
- Farzaneh Rashidi Fakari ,
- Masoudeh Babakhanian ,
- Nasibeh Roozbeh ,
- Masumeh Ghazanfarpour
Views241See moreAbstract
Objective
Different drugs are used to treat mastalgia, such as danazol and bromocriptine, and both are associated with side effects, due to which most of women and healthcare providers are interested in herbal medicines. Therefore we aim to study the effectiveness of phytoestrogens on the severity of cyclic mastalgia.
Methods
To carry out the present study, English electronic resources such as the Cochrane Library, ISI Web of Science, Scopus, and PubMed were used systematically and with no time limitation up to February 10, 2020.
Results
In total, 20 studies were included in the present meta-analysis. The results of the meta-analysis showed that herbal medicines versus the control group (standard mean difference [SMD] = - 0.585; 95% confidence interval [CI]: - 0.728–- 0.44; heterogeneity; p = 0.02; I2 = 42%), herbal medicines versus the B group (SMD = - 0.59; 95%CI: - 0.75–- 0.44; heterogeneity; p = 0.03; I2 = 42%), and its subgroups, such as phytoestrogen (SMD = - 0.691; 95%CI: - 0.82–- 0.55; heterogeneity; p = 0.669; I2 = 0%), Vitex-agnus-castus (SMD = - 0.642; 95%CI: - 0.84–- 0.44; p < 0.001; p = 203; I2 = 32%), flaxseed (SMD = - 0.63; 95%CI: - 0.901–- 0.367; p = 0.871; I2 = 0%), and evening primrose (SMD= - 0.485; 95%CI:- 0.84–- 0.12; p = 0.008; heterogeneity; p = 0.06; I2 = 56%] may have effective and helpful effects on improving cyclic breast mastalgia. Also, chamomile, isoflavone, cinnamon, and nigella sativa significantly reduced mastalgia symptoms.
Conclusion
Herbal medicines and their subgroups may have effective and helpful effects on improving cyclic breast mastalgia. The findings of our meta-analysis must be done cautiously because low methodological quality in some evaluated studies of this systematic review.
Views241This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Summary
Review ArticleThe Effectiveness of Herbal Medicines on Cyclic Mastalgia: A Systematic Review on Meta-analysis
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(10):972-985
01-23-2022- Firoozeh Mirzaee ,
- Farzaneh Rashidi Fakari ,
- Masoudeh Babakhanian ,
- Nasibeh Roozbeh ,
- Masumeh Ghazanfarpour
Views241See moreAbstract
Objective
Different drugs are used to treat mastalgia, such as danazol and bromocriptine, and both are associated with side effects, due to which most of women and healthcare providers are interested in herbal medicines. Therefore we aim to study the effectiveness of phytoestrogens on the severity of cyclic mastalgia.
Methods
To carry out the present study, English electronic resources such as the Cochrane Library, ISI Web of Science, Scopus, and PubMed were used systematically and with no time limitation up to February 10, 2020.
Results
In total, 20 studies were included in the present meta-analysis. The results of the meta-analysis showed that herbal medicines versus the control group (standard mean difference [SMD] = - 0.585; 95% confidence interval [CI]: - 0.728–- 0.44; heterogeneity; p = 0.02; I2 = 42%), herbal medicines versus the B group (SMD = - 0.59; 95%CI: - 0.75–- 0.44; heterogeneity; p = 0.03; I2 = 42%), and its subgroups, such as phytoestrogen (SMD = - 0.691; 95%CI: - 0.82–- 0.55; heterogeneity; p = 0.669; I2 = 0%), Vitex-agnus-castus (SMD = - 0.642; 95%CI: - 0.84–- 0.44; p < 0.001; p = 203; I2 = 32%), flaxseed (SMD = - 0.63; 95%CI: - 0.901–- 0.367; p = 0.871; I2 = 0%), and evening primrose (SMD= - 0.485; 95%CI:- 0.84–- 0.12; p = 0.008; heterogeneity; p = 0.06; I2 = 56%] may have effective and helpful effects on improving cyclic breast mastalgia. Also, chamomile, isoflavone, cinnamon, and nigella sativa significantly reduced mastalgia symptoms.
Conclusion
Herbal medicines and their subgroups may have effective and helpful effects on improving cyclic breast mastalgia. The findings of our meta-analysis must be done cautiously because low methodological quality in some evaluated studies of this systematic review.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. - Firoozeh Mirzaee
-
Review Article
Efficacy of Hormonal and Nonhormonal Approaches to Vaginal Atrophy and Sexual Dysfunctions in Postmenopausal Women: A Systematic Review
- Ayane Cristine Alves Sarmento ,
- Ana Paula Ferreira Costa ,
- Juliana Lírio ,
- José Eleutério Jr ,
- Pedro Vieira Baptista , [ ... ],
- Ana Katherine Gonçalves
01-23-2022
Summary
Review ArticleEfficacy of Hormonal and Nonhormonal Approaches to Vaginal Atrophy and Sexual Dysfunctions in Postmenopausal Women: A Systematic Review
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(10):986-994
01-23-2022- Ayane Cristine Alves Sarmento ,
- Ana Paula Ferreira Costa ,
- Juliana Lírio ,
- José Eleutério Jr ,
- Pedro Vieira Baptista ,
- Ana Katherine Gonçalves
Views303See moreAbstract
Objective
To evaluate the efficacy of the hormonal and nonhormonal approaches to symptoms of sexual dysfunction and vaginal atrophy in postmenopausal women.
Data Sources
We conducted a search on the PubMed, Embase, Scopus, Web of Science, SciELO, the Cochrane Central Register of Controlled Trials (CENTRAL), and Cumulative Index to Nursing and Allied Health Literature (CINAHL) databases, as well as on clinical trial databases. We analyzed studies published between 1996 and May 30, 2020. No language restrictions were applied.
Selection of Studies
We selected randomized clinical trials that evaluated the treatment of sexual dysfunction in postmenopausal women.
Data Collection
Three authors (ACAS, APFC, and JL) reviewed each article based on its title and abstract. Relevant data were subsequently taken from the full-text article. Any discrepancies during the review were resolved by consensus between all the listed authors.
Data Synthesis
A total of 55 studies were included in the systematic review. The approaches tested to treat sexual dysfunction were as follows: lubricants and moisturizers (18 studies); phytoestrogens (14 studies); dehydroepiandrosterone (DHEA; 8 studies); ospemifene (5 studies); vaginal testosterone (4 studies); pelvic floor muscle exercises (2 studies); oxytocin (2 studies); vaginal CO2 laser (2 studies); lidocaine (1 study); and vitamin E vaginal suppository (1 study).
Conclusion
We identified literature that lacks coherence in terms of the proposed treatments and selected outcome measures. Despite the great diversity in treatment modalities and outcome measures, the present systematic review can shed light on potential targets for the treatment, which is deemed necessary for sexual dysfunction, assuming that most randomized trials were evaluated with a low risk of bias according to the Cochrane Collaboration risk of bias tool. The present review is registered with the International Prospective Register of Systematic Reviews (PROSPERO; CRD42018100488).
Views303This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Summary
Review ArticleEfficacy of Hormonal and Nonhormonal Approaches to Vaginal Atrophy and Sexual Dysfunctions in Postmenopausal Women: A Systematic Review
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(10):986-994
01-23-2022- Ayane Cristine Alves Sarmento ,
- Ana Paula Ferreira Costa ,
- Juliana Lírio ,
- José Eleutério Jr ,
- Pedro Vieira Baptista ,
- Ana Katherine Gonçalves
Views303See moreAbstract
Objective
To evaluate the efficacy of the hormonal and nonhormonal approaches to symptoms of sexual dysfunction and vaginal atrophy in postmenopausal women.
Data Sources
We conducted a search on the PubMed, Embase, Scopus, Web of Science, SciELO, the Cochrane Central Register of Controlled Trials (CENTRAL), and Cumulative Index to Nursing and Allied Health Literature (CINAHL) databases, as well as on clinical trial databases. We analyzed studies published between 1996 and May 30, 2020. No language restrictions were applied.
Selection of Studies
We selected randomized clinical trials that evaluated the treatment of sexual dysfunction in postmenopausal women.
Data Collection
Three authors (ACAS, APFC, and JL) reviewed each article based on its title and abstract. Relevant data were subsequently taken from the full-text article. Any discrepancies during the review were resolved by consensus between all the listed authors.
Data Synthesis
A total of 55 studies were included in the systematic review. The approaches tested to treat sexual dysfunction were as follows: lubricants and moisturizers (18 studies); phytoestrogens (14 studies); dehydroepiandrosterone (DHEA; 8 studies); ospemifene (5 studies); vaginal testosterone (4 studies); pelvic floor muscle exercises (2 studies); oxytocin (2 studies); vaginal CO2 laser (2 studies); lidocaine (1 study); and vitamin E vaginal suppository (1 study).
Conclusion
We identified literature that lacks coherence in terms of the proposed treatments and selected outcome measures. Despite the great diversity in treatment modalities and outcome measures, the present systematic review can shed light on potential targets for the treatment, which is deemed necessary for sexual dysfunction, assuming that most randomized trials were evaluated with a low risk of bias according to the Cochrane Collaboration risk of bias tool. The present review is registered with the International Prospective Register of Systematic Reviews (PROSPERO; CRD42018100488).
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. - Ayane Cristine Alves Sarmento
-
Review Article
The Effects of Hysterectomy on Urinary and Sexual Functions of Women with Cervical Cancer: A Systematic Review
- Mariana Alves Firmeza ,
- Camila Teixeira Moreira Vasconcelos ,
- José Ananias Vasconcelos Neto ,
- Luiz Gustavo de Oliveira Brito ,
- Flávio Mendes Alves , [ ... ],
- Natália Maria de Vasconcelos Oliveira
10-07-2022
Summary
Review ArticleThe Effects of Hysterectomy on Urinary and Sexual Functions of Women with Cervical Cancer: A Systematic Review
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(8):790-796
10-07-2022- Mariana Alves Firmeza ,
- Camila Teixeira Moreira Vasconcelos ,
- José Ananias Vasconcelos Neto ,
- Luiz Gustavo de Oliveira Brito ,
- Flávio Mendes Alves ,
- Natália Maria de Vasconcelos Oliveira
Views232See moreAbstract
Objective
This systematic review aims at describing the prevalence of urinary and sexual symptoms among women who underwent a hysterectomy for cervical cancer.
Methods
A systematic search in six electronic databases was performed, in September 2019, by two researchers. The text search was limited to the investigation of prevalence or occurrence of lower urinary tract symptoms (LUTS) and sexual dysfunctions in women who underwent a hysterectomy for cervical cancer. For search strategies, specific combinations of terms were used.
Results
A total of 8 studies, published between 2010 and 2018, were included in the sample. The average age of the participants ranged from 40 to 56 years, and the dysfunctions predominantly investigated in the articles were urinary symptoms (n= 8). The rates of urinary incontinence due to radical abdominal hysterectomy ranged from 7 to 31%. The same dysfunction related to laparoscopic radical hysterectomy varied from 25 to 35% and to laparoscopic nerve sparing radical hysterectomy varied from 25 to 47%. Nocturia ranged from 13%, before treatment, to 30%, after radical hysterectomy. The prevalence rates of dyspareunia related to laparoscopic radical hysterectomy and laparoscopic nerve sparing radical hysterectomy ranged from 5 to 16% and 7 to 19% respectively. The difficulty in having orgasm was related to laparoscopic radical hysterectomy (10 to 14%) and laparoscopic nerve sparing radical hysterectomy (9 to 19%).
Conclusion
Urinary and sexual dysfunctions after radical hysterectomy to treat cervical cancer are frequent events. The main reported disorders were urinary incontinence and dyspareunia.
Views232This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Summary
Review ArticleThe Effects of Hysterectomy on Urinary and Sexual Functions of Women with Cervical Cancer: A Systematic Review
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(8):790-796
10-07-2022- Mariana Alves Firmeza ,
- Camila Teixeira Moreira Vasconcelos ,
- José Ananias Vasconcelos Neto ,
- Luiz Gustavo de Oliveira Brito ,
- Flávio Mendes Alves ,
- Natália Maria de Vasconcelos Oliveira
Views232See moreAbstract
Objective
This systematic review aims at describing the prevalence of urinary and sexual symptoms among women who underwent a hysterectomy for cervical cancer.
Methods
A systematic search in six electronic databases was performed, in September 2019, by two researchers. The text search was limited to the investigation of prevalence or occurrence of lower urinary tract symptoms (LUTS) and sexual dysfunctions in women who underwent a hysterectomy for cervical cancer. For search strategies, specific combinations of terms were used.
Results
A total of 8 studies, published between 2010 and 2018, were included in the sample. The average age of the participants ranged from 40 to 56 years, and the dysfunctions predominantly investigated in the articles were urinary symptoms (n= 8). The rates of urinary incontinence due to radical abdominal hysterectomy ranged from 7 to 31%. The same dysfunction related to laparoscopic radical hysterectomy varied from 25 to 35% and to laparoscopic nerve sparing radical hysterectomy varied from 25 to 47%. Nocturia ranged from 13%, before treatment, to 30%, after radical hysterectomy. The prevalence rates of dyspareunia related to laparoscopic radical hysterectomy and laparoscopic nerve sparing radical hysterectomy ranged from 5 to 16% and 7 to 19% respectively. The difficulty in having orgasm was related to laparoscopic radical hysterectomy (10 to 14%) and laparoscopic nerve sparing radical hysterectomy (9 to 19%).
Conclusion
Urinary and sexual dysfunctions after radical hysterectomy to treat cervical cancer are frequent events. The main reported disorders were urinary incontinence and dyspareunia.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. - Mariana Alves Firmeza
-
Review Article
Management Strategies for Sexuality Complaints after Gynecologic Cancer: A Systematic Review
- Luciane Machado Pizetta ,
- Augusto da Cunha Reis ,
- Mirian Picinini Méxas ,
- Vanessa de Almeida Guimarães ,
- Carmen Lucia de Paula
09-29-2022
Summary
Review ArticleManagement Strategies for Sexuality Complaints after Gynecologic Cancer: A Systematic Review
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(10):962-971
09-29-2022- Luciane Machado Pizetta ,
- Augusto da Cunha Reis ,
- Mirian Picinini Méxas ,
- Vanessa de Almeida Guimarães ,
- Carmen Lucia de Paula
Views150See moreAbstract
Objective
To explore the main sexuality complaints of gynecologic cancer survivors after treatment and to identify the care strategies provided.
Data Source
Searches were conducted in six electronic databases: Scopus, Web of Science, LILACS, MEDLINE, PsychINFO, and EMBASE.
Study Selection
Articles published between 2010 and 2020 were selected and the following descriptors were used in the English language: female genital neoplasms and gynaecological cancer. The methodological quality of the studies used the Mixed Methods Appraisal Tool (MMAT).
Data Collection
The primary data extracted were: names of the authors, year of publication, country of origin, objective and type of study, data collection instrument, sample size and age range, types of cancer, and symptoms affected with the strategies adopted.
Data Summary
A total of 34 out of 2,536 screened articles were included. The main strategies found for patient care were patient-clinician communication, practices for sexuality care, individualized care plan, multiprofessional team support, and development of rehabilitation programs. For sexuality care, the most common practices are pelvic physiotherapy sessions and the use of vaginal gels and moisturizers.
Conclusion
The main complaints identified in the scientific literature were low libido and lack of interest in sexual activity, vaginal dryness, pain during sexual intercourse, and stenosis. Different care strategies may be adopted, such as follow-up with a multidisciplinary health team and sexual health rehabilitation programs, which could minimize these symptoms and ensure the quality of life of patients.
Views150This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Summary
Review ArticleManagement Strategies for Sexuality Complaints after Gynecologic Cancer: A Systematic Review
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(10):962-971
09-29-2022- Luciane Machado Pizetta ,
- Augusto da Cunha Reis ,
- Mirian Picinini Méxas ,
- Vanessa de Almeida Guimarães ,
- Carmen Lucia de Paula
Views150See moreAbstract
Objective
To explore the main sexuality complaints of gynecologic cancer survivors after treatment and to identify the care strategies provided.
Data Source
Searches were conducted in six electronic databases: Scopus, Web of Science, LILACS, MEDLINE, PsychINFO, and EMBASE.
Study Selection
Articles published between 2010 and 2020 were selected and the following descriptors were used in the English language: female genital neoplasms and gynaecological cancer. The methodological quality of the studies used the Mixed Methods Appraisal Tool (MMAT).
Data Collection
The primary data extracted were: names of the authors, year of publication, country of origin, objective and type of study, data collection instrument, sample size and age range, types of cancer, and symptoms affected with the strategies adopted.
Data Summary
A total of 34 out of 2,536 screened articles were included. The main strategies found for patient care were patient-clinician communication, practices for sexuality care, individualized care plan, multiprofessional team support, and development of rehabilitation programs. For sexuality care, the most common practices are pelvic physiotherapy sessions and the use of vaginal gels and moisturizers.
Conclusion
The main complaints identified in the scientific literature were low libido and lack of interest in sexual activity, vaginal dryness, pain during sexual intercourse, and stenosis. Different care strategies may be adopted, such as follow-up with a multidisciplinary health team and sexual health rehabilitation programs, which could minimize these symptoms and ensure the quality of life of patients.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. - Luciane Machado Pizetta
-
Review Article
The Effect of Neuromodulatory Drugs on the Intensity of Chronic Pelvic Pain in Women: A Systematic Review
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(9):891-898
08-31-2022
Summary
Review ArticleThe Effect of Neuromodulatory Drugs on the Intensity of Chronic Pelvic Pain in Women: A Systematic Review
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(9):891-898
08-31-2022Views147See moreAbstract
Objective:
To evaluate the effect of neuromodulatory drugs on the intensity of chronic pelvic pain (CPP) in women.
Data sources:
Searches were carried out in the PubMed, Cochrane Central, Embase, Lilacs, OpenGrey, and Clinical Trials databases.
Selection of studies:
The searches were carried out by two of the authors, not delimiting publication date or original language. The following descriptors were used: chronic pelvic pain in women OR endometriosis, associated with MESH/ENTREE/DeCS: gabapentinoids, gabapentin, amitriptyline, antidepressant, pregabalin, anticonvulsant, sertraline, duloxetine, nortriptyline, citalopram, imipramine, venlafaxine, neuromodulation drugs, acyclic pelvic pain, serotonin, noradrenaline reuptake inhibitors, and tricyclic antidepressants, with the Boolean operator OR. Case reports and systematic reviews were excluded.
Data collection:
The following data were extracted: author, year of publication, setting, type of study, sample size, intervention details, follow-up time, and results.
Data synthesis:
A total of 218 articles were found, with 79 being excluded because they were repeated, leaving 139 articles for analysis: 90 were excluded in the analysis of the titles, 37 after reading the abstract, and 4 after reading the articles in full, and 1 could not be found, therefore, leaving 7 articles that were included in the review.
Conclusion:
Most of the studies analyzed have shown pain improvement with the help of neuromodulators for chronic pain. However, no improvement was found in the study with the highest statistical power. There is still not enough evidence that neuromodulatory drugs reduce the intensity of pain in women with CPP.
Views147This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Summary
Review ArticleThe Effect of Neuromodulatory Drugs on the Intensity of Chronic Pelvic Pain in Women: A Systematic Review
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(9):891-898
08-31-2022Views147See moreAbstract
Objective:
To evaluate the effect of neuromodulatory drugs on the intensity of chronic pelvic pain (CPP) in women.
Data sources:
Searches were carried out in the PubMed, Cochrane Central, Embase, Lilacs, OpenGrey, and Clinical Trials databases.
Selection of studies:
The searches were carried out by two of the authors, not delimiting publication date or original language. The following descriptors were used: chronic pelvic pain in women OR endometriosis, associated with MESH/ENTREE/DeCS: gabapentinoids, gabapentin, amitriptyline, antidepressant, pregabalin, anticonvulsant, sertraline, duloxetine, nortriptyline, citalopram, imipramine, venlafaxine, neuromodulation drugs, acyclic pelvic pain, serotonin, noradrenaline reuptake inhibitors, and tricyclic antidepressants, with the Boolean operator OR. Case reports and systematic reviews were excluded.
Data collection:
The following data were extracted: author, year of publication, setting, type of study, sample size, intervention details, follow-up time, and results.
Data synthesis:
A total of 218 articles were found, with 79 being excluded because they were repeated, leaving 139 articles for analysis: 90 were excluded in the analysis of the titles, 37 after reading the abstract, and 4 after reading the articles in full, and 1 could not be found, therefore, leaving 7 articles that were included in the review.
Conclusion:
Most of the studies analyzed have shown pain improvement with the help of neuromodulators for chronic pain. However, no improvement was found in the study with the highest statistical power. There is still not enough evidence that neuromodulatory drugs reduce the intensity of pain in women with CPP.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. -
Review Article
Coronavirus Disease 2019 Vaccination for Cancer Patients: Risk or Benefit?
- Bruno Eduardo Pereira Laporte ,
- Estela Gelain Junges Laporte ,
- Paula Fonseca Aarestrup ,
- Matheus Fonseca Aarestrup ,
- Fernando Monteiro Aarestrup
08-15-2022
Summary
Review ArticleCoronavirus Disease 2019 Vaccination for Cancer Patients: Risk or Benefit?
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(6):602-608
08-15-2022- Bruno Eduardo Pereira Laporte ,
- Estela Gelain Junges Laporte ,
- Paula Fonseca Aarestrup ,
- Matheus Fonseca Aarestrup ,
- Fernando Monteiro Aarestrup
Views143See moreAbstract
Objective
The aim of the present study is to list the published clinical trials on coronavirus disease 2019 (COVID-19) vaccines, to describe the mechanism of action of the identified vaccines, and to identify protocols regarding safety, status, and prioritization of cancer patients for vaccination.
Methods
This is a systematic review with a limited literature search conducted by an information specialist; key resources such as PubMed and websites of major cancer organizations were searched. The main search terms were COVID-19, vaccination, cancer, and breast and gynecological cancers.
Results
Cancer patients infected with the new coronavirus are at high risk of complications and death, but we still know little about the risks and benefits of vaccination for COVID-19 in these patients. In an ideal scenario, all cancer patients should have their immunization status updated before beginning treatment, but this is not always possible.
Conclusion
Patients with breast or gynecological cancers who are receiving treatment or are in the 5-year posttreatment period should be included in the priority group for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination.
Views143This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Summary
Review ArticleCoronavirus Disease 2019 Vaccination for Cancer Patients: Risk or Benefit?
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(6):602-608
08-15-2022- Bruno Eduardo Pereira Laporte ,
- Estela Gelain Junges Laporte ,
- Paula Fonseca Aarestrup ,
- Matheus Fonseca Aarestrup ,
- Fernando Monteiro Aarestrup
Views143See moreAbstract
Objective
The aim of the present study is to list the published clinical trials on coronavirus disease 2019 (COVID-19) vaccines, to describe the mechanism of action of the identified vaccines, and to identify protocols regarding safety, status, and prioritization of cancer patients for vaccination.
Methods
This is a systematic review with a limited literature search conducted by an information specialist; key resources such as PubMed and websites of major cancer organizations were searched. The main search terms were COVID-19, vaccination, cancer, and breast and gynecological cancers.
Results
Cancer patients infected with the new coronavirus are at high risk of complications and death, but we still know little about the risks and benefits of vaccination for COVID-19 in these patients. In an ideal scenario, all cancer patients should have their immunization status updated before beginning treatment, but this is not always possible.
Conclusion
Patients with breast or gynecological cancers who are receiving treatment or are in the 5-year posttreatment period should be included in the priority group for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. - Bruno Eduardo Pereira Laporte
Review Article Archives - Page 7 of 16 - Revista Brasileira de Ginecologia e Obstetrícia
